PRINT THIS PAGE

US venture firm CMEA names Haseltine as senior life sciences advisor

CMEA, the US IT and life sciences venture firm, has named William Haseltine as a senior life sciences advisor. Haseltine is chairman and chief executive of Human Genome Sciences and has founded no less than seven biotechnology companies.

Tom Baruch, managing general partner of CMEA, said, 'We are delighted to be working with Dr Haseltine. He brings a unique perspective based on his scientific accomplishments and his experience as a successful innovator, entrepreneur, and manager.'

Firms Haseltine founded include Dendreon, Diversa, and Human Genome Sciences. Haseltine was also an advisor to Venture Capital Fund Healthcare Ventures, when he participated in the creation of 20 other biotech firms, including Medimmune.

Haseltine has published 250 scientific papers and written various books; he also founded The Journal of AIDS Research and Retrovirology, and The Journal of Regenerative Medicine.

CMEA invests in both early and late stage companies. It manages six funds and has $771m under management.

The firm has been an early stage investor in Silicon Valley companies such as Flextronics, Maxygen, Silicon Spice, Syrrx (recently purchased by Takeda), Symyx, and Virologic. The current CMEA portfolio includes Alexza, Alien Technology, Altus, Ambrx, Bayhill Therapeutics, Biomimetic, Codexis, Entropic, Intermolecular, Perlegen, and Predix, among others.

Copyright © 2005 AltAssets